TransMedics Faces 2nd Panel Date Postponement

Will the third time be the charm?

The company said the postponement will give the US FDA additional time to review trial data.

FDA Advisory Committee Feature image

TransMedics will need to wait a bit longer for its heart transplant device to be considered by a US Food and Drug Administration panel.

The Circulatory System Devices Panel virtual meeting on the TransMedics Organ Care System (OCS) Heart had been scheduled for 7...

More from Cardiology

More from Device Area